<span item_type="fundamental" item_id="e849754a7e91ce8e7c85e4cd96bd959f" counter_id="ST/US/ZEOX" env="prod"></span><span item_type="announcement" item_id="528063657151954945" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 1.149 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.22.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Revenues</strong>: For the three months ended April 30, 2025, revenues were $1,149,000, a slight increase from $1,131,000 in the same period in 2024. For the six months ended April 30, 2025, revenues were $2,239,000, a decrease from $2,285,000 in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1557376/000182912625004512/zeoscientifix_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Gross Profit</strong>: For the three months ended April 30, 2025, gross profit was $893,000 (77.7% of revenues), compared to $847,000 (74.9% of revenues) in the same period in 2024. For the six months ended April 30, 2025, gross profit was $1,792,000 (80.0% of revenues), compared to $1,842,000 (80.6% of revenues) in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1557376/000182912625004512/zeoscientifix_10q.htm"></span></li><li><strong>Net Loss</strong>: For the three months ended April 30, 2025, net loss was - $1,391,000, compared to - $1,399,000 in the same period in 2024. For the six months ended April 30, 2025, net loss was - $2,634,000, compared to - $2,439,000 in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1557376/000182912625004512/zeoscientifix_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities was - $78,000 for the six months ended April 30, 2025, compared to - $990,000 in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1557376/000182912625004512/zeoscientifix_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Revenue by Product</strong>: For the three months ended April 30, 2025, higher concentration allogenic aesthetic biologics contributed $335,000 (29.2% of revenues), lower concentration allogenic aesthetic biologics contributed $473,000 (41.2% of revenues), and PPX™ contributed $282,000 (24.5% of revenues).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1557376/000182912625004512/zeoscientifix_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focusing on completing approved clinical studies and obtaining FDA approval for additional studies. It is also expanding sales internationally and developing new product offerings to mitigate potential risks associated with FDA regulations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1557376/000182912625004512/zeoscientifix_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring further development of products for topical aesthetic applications and has launched a collaborative product, “ZEO HAIR GROW™ Powered By Exotropin™”.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1557376/000182912625004512/zeoscientifix_10q.htm"></span></li></ul>

Zeo ScientifiX, Inc. | 10-Q: FY2025 Q2 Revenue: USD 1.149 M